Goldman Small Cap Research Issues Research Update and

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

May 28, 2013 at 9:00 AM

Goldman Small Cap Research Issues Research Update and Valuation on Nuvilex, Inc.

BALTIMORE, MD--(Marketwired - May 28, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, has issued a new research report which provides an updated valuation of Nuvilex Inc. ( OTCQB : NVLX ), an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of medical marijuana for use in oncology treatment.

Nuvilex is primarily known for its proprietary, multi-functional, biomedical therapeutic enhancement platform which has been used in clinical trials, notably a Phase 2 pancreatic cancer trial that generated very favorable results. This platform, which essentially serves as an existing therapy booster, is based upon its live-cell encapsulation technology and delivery system and enhances the quality of life.

In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.

"After performing further due diligence on the Company and the oncology treatment space, we felt compelled to raise our valuation Nuvilex. This change is based upon a first-time value for the Company's breast cancer indication and a potential re-valuation of the Company's platform as a result of the recently announced slew of nanobiotechnology industry development deals in oncology that could be worth nearly $1 billion. Word that the Company is gearing up for future trials also played a factor in this valuation increase."

To view Nuvilex reports and articles or to download the report in its entirety, please visit www.goldmanresearch.com .

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com .

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com .

About Nuvilex, Inc. ( OTCQB : NVLX ): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com .

Goldman Small Cap Research Rob Goldman Analyst 410-609-7100 rob@goldmanresearch.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leadership Shake-Up at Equity LifeStyle Properties

Shifting Gears at the Top When the calendar flips to 2027, Equity LifeStyle Properties, Inc. (NYSE:ELS) will be kicking off the new year with a fresh lineup at the helm. After 13 long years steering the ship, Marguerite Nader is moving into the role of Executive Vice Chair of the Board of Directors, paving the way for Patrick Waite to step into her shoes as President and...

Slippery Rock University Launches $35M Fundraising Effort

The $35 Million Vision So, Slippery Rock University decides it's time to beef up their resources with a bold $35 million fundraising campaign, aptly titled “Because this is The Rock.” It's been over 30 years since SRU last rolled out a comprehensive campaign, which makes this push not just ambitious but also crucial. As of the public phase launch on October 23,...

U.S. Gold Corp. Gears Up for Key October Event

Marking Calendars for the Emerging Growth Showdown There's nothing quite like the buzz leading up to an event where you know someone’s either gonna make a splash or barely leave a ripple. U.S. Gold Corp. is drawing some attention ahead of the Emerging Growth Conference on October 29, 2026. This ain't just any corporate dog-and-pony show—it's a chance for the Gold...

Housing Transition: Unlocking the Trillion-Dollar Pathway

A Trillion-Dollar Balancing Act at COP31 The housing market: one giant balancing act, now with a trillion bucks at stake. The Sustainable Real Estate Forum (SREF) didn't hold back in their new white paper, "The Trillion-Dollar Housing Transition." They've outlined the monumental shift needed to get our housing not just affordable, but sustainable too. The Lay of the Land...

Altea Targets US Market, Appoints Rodrick VP Amid Expansion

Wading into the murky waters of U.S. healthcare insurance isn't for the faint of heart, but Altea's making its move. Backed by MISSION, they're banking on a niche strategy by tapping veteran Justin Rodrick as Vice President. Their tactic? Aim squarely at the under-served segment of small to mid-sized medical and healthcare facilities. The play's bold, and if Rodrick's got...

Ellucian's Cloud Hat-Trick: Leading AI in Education

Turning the Dial on Cloud Innovation What’s gripping the talk of the town? It's the powerhouse, Ellucian, clinching the 2026 Stratus Award for Cloud Computing in the Education category, marking a third straight victory. It’s a trifecta that signals something big in the world of higher ed tech. But what does it mean for investors and the sector at large? Unpacking the...

Hengrui Pharma: Innovating Oncology on Global Stage

Setting the Global Stage for Chinese Pharmaceutical Innovation Ah, China is no longer just the factory of the world; it's rolling its sleeves up and getting deep into the pharma game. Hengrui Pharma, a heavyweight in China's pharmaceutical scene, just pulled off a commendable performance at the European Society for Medical Oncology (ESMO) Congress 2026 over in Madrid....

Investors Shaken by Better Home’s 28.5% Plunge

Pull up a chair, because Better Home & Finance Holding Company (NASDAQ: BETR) just threw its investors into a frenzy. Mayhem hit when their stock nosedived 28.5% on a single day—May 7, 2026. Let’s untangle what happened and why every shareholder should circle November 20 on their calendar. Unpacking the Fall: A Dive Into Hard Truths So, between mid-March and early May...

Socket Mobile Moves Listing from Nasdaq to OTCID

When Socket Mobile decided to jump ship from Nasdaq to the OTCID Market, they sure shook things up. We have a company that’s taking a bold leap, moving off the big-time Nasdaq stage to the less glitzy, but arguably more financially forgiving, floors of the OTC Markets. Why Leave Nasdaq? Cost-Cutting for Core Growth Now, above all else, the rationale screams ‘money...

Right Heart Failure Gains Recognition as Its Own Syndrome

Changing the Narrative on Right Heart Failure How often do we see right heart failure (RHF) brushed aside like some understudy in the grand play of cardiovascular disease? Far too often, according to the Heart Failure Society of America (HFSA). They're here to shift that narrative, demanding RHF be recognized for what it truly is: a distinct clinical syndrome. Forget...